| |
|
|
COBIS tenants
We’ve designed COBIS to be home to a diverse group of organizations across the biotech innovation spectrum. Everything you need is at hand. And new connections happen every day. Below you can meet the tenants in COBIS, that have joined us so far.
| Affitech AS is a publicly traded (NASDAQ OMX Copenhagen) therapeutic antibody company headquartered in Copenhagen, Denmark with R&D facilities in Oslo, Norway. The company utilizes a range of proprietary antibody technologies for the discovery of therapeutic antibodies for application in oncology, inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is Affitech A/S’s premier technology platform for the isolation of lead antibodies to cell surface targets. Several of the Company's proprietary drug candidates were generated by CBAS™.
|
| Aquaporin is working on the development of a unique and revolutionising membrane technology used for the purification of water by use of nature’s own method. The target is to create the cleanest water in the world for industrial purposes and an aquaporin membrane for desalination of seawater.
|
| Aros Pharma is focusing on novel pharmaceuticals targeting unmet needs within pain relief, infectious disease, inflammation, respiratory diseases and immuno-suppressed patients.
Projects of interest are in late pre-clinical, phase I or early phase II.
|
| BIOPHARM FORWARD ApS is a privately owned Danish consulting firm specializing in identification, evaluation and development of biotechnological and pharmaceutical projects, business opportunities and investments. We provide services to healthcare organizations and the pharmaceutical, biotech and life science investment industries. Our guidance and expertise is based on a combination of scientific and therapeutic insight, extensive development experience, and a deep understanding of the biotechnology and pharmaceutical value chain.
|
| BIOSTRAT provides strategic decision making services to pharmaceutical, life science, and biotech companies. BIOSTRAT specialises in assisting companies in making strategic decisions with regards to corporate strategy, partnering, licensing, and M&A.
|
| DANISH BIOTECH is a trade organization for Danish biotech companies with the aim to promote opportunities for biotechnology research, development and production in Denmark and perform common business interests in this context, both nationally and internationally.
DANISH BIOTECH members are private companies in Denmark who research, develops or produces pharmaceuticals or other products with a significant content of biotechnology (biotech companies) and their parent companies and investment funds that are active owners of biotech companies.
Membership can be obtained on www.danskbiotek.dk.
|
| EpiTherapeutics is developing novel innovative cancer drugs based on the world leading research in epigenetics conducted by Professor Kristian Helin and his group at Biotech Research & Innovation Centre (BRIC) at University of Copenhagen.
|
| Department of Research & Innovation supports an increased interaction with industry, government and university stakeholders. The support is done by concentration of expertise in business cooperation in a broad sense, including patenting and cooperation, as well as external financing, particularly in the EU area.
|
| Fischer BioConsult provides services relating to financing, business development and product development within the biotech sector. Per Fischer has more than 15 years experience from biotech, pharma and consulting, and has worked for more than 25 clients over a period of 4 years.
|
| Medicon A/S conducts clinical trials in phase II, phase III and phase IV levels, primaly within rheaumatology - we are also active on other areas such as RLS(restless legs) and migraine. we continually work on expanding our level of expertise to other areas.
|
| Orphazyme develops pharmaceuticals that target lysosomes. The company is dedicated to developing a novel class of therapeutics for the treatment of lysosomal storage diseases, a group of debilitating genetic disorders.
|
| Based on extensive hands on experience Qsol provide services related to the laboratory to biotech, pharmaceutical, and life science companies. The services include tailor made documentation systems, CMC documentation (Analytical methods, specifications, stability, IND etc.), education in various regulatory and laboratory related topics, audit in analytical laboratories, review of CRO material and technical due diligence.
Benefit from years of experience both from industry and the Danish Medicines Agency. This combined with extensive laboratory experience makes Qsol a unique business partner.
|
| The Research Support Unit is part of the Capital Region of Denmark. Our main objective is to attract national and international funding for the region’s researchers. We perform many types of tasks, for instance, advising and providing practical support for researchers writing applications.
|
| Serendex develops novel therapies for critical lung diseases. We are entirely focused on inhaled drug delivery because topical (local) therapy is usually much safer than systemic therapy.
|
| Tectra was established by the Capital Region in 2007 and is a horizontal unit for technology transfer. The unit serves all the regional hospital and psychiatry around patenting and commercialization of inventions made at the regional hospital and offer legal assistance in concluding agreements.
|
| Executive assistance, management support and traditional sales/marketing and secretarial assistance on an hourly basis.
|
| The Brain Prize will be awarded to one or more scientists who have distinguished themselves by an outstanding contribution to European brain research. The € 1 million prize is a personal prize and will be awarded for the first time in May 2011. Awards will be followed by an extensive outreach programme organised together with the major Danish universities.
|
| Thrombologic is a small seed-capital biotech developing new discoveries from Rigshospitalet, and a leading frontier investigator to develop life-saving therapies for critically ill patients suffering from sepsis and multiple organ failure. With the backing of seed investment companies Novo Seeds and CATScience, Thrombologic’s goals is to take its unique and proprietary approach from theoretical idea to experimental data – and produce enough data to support a clinical proof of concept study where both the effect and the safety of the treatment can be thoroughly tested.
|
|
|
